- Home
- ACRV vs MDAI Comparison
ACRV vs MDAI Comparison
Compare ACRV & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- MDAI
- Stock Information
- Founded
- ACRV 2018
- MDAI 2013
- Country
- ACRV United States
- MDAI United States
- Employees
- ACRV N/A
- MDAI 78
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- MDAI Medical/Dental Instruments
- Sector
- ACRV Health Care
- MDAI Health Care
- Exchange
- ACRV Nasdaq
- MDAI Nasdaq
- Market Cap
- ACRV 47.8M
- MDAI 51.9M
- IPO Year
- ACRV 2022
- MDAI N/A
- Fundamental
- Price
- ACRV $1.52
- MDAI $1.94
- Analyst Decision
- ACRV Buy
- MDAI Strong Buy
- Analyst Count
- ACRV 7
- MDAI 1
- Target Price
- ACRV $17.40
- MDAI $3.50
- AVG Volume (30 Days)
- ACRV 3.4M
- MDAI 273.8K
- Earning Date
- ACRV 11-12-2025
- MDAI 11-05-2025
- Dividend Yield
- ACRV N/A
- MDAI N/A
- EPS Growth
- ACRV N/A
- MDAI N/A
- EPS
- ACRV N/A
- MDAI N/A
- Revenue
- ACRV N/A
- MDAI $27,549,000.00
- Revenue This Year
- ACRV N/A
- MDAI N/A
- Revenue Next Year
- ACRV $805.34
- MDAI $60.05
- P/E Ratio
- ACRV N/A
- MDAI N/A
- Revenue Growth
- ACRV N/A
- MDAI 22.27
- 52 Week Low
- ACRV $1.05
- MDAI $0.82
- 52 Week High
- ACRV $10.00
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- ACRV 56.53
- MDAI 42.21
- Support Level
- ACRV $1.30
- MDAI $1.78
- Resistance Level
- ACRV $2.67
- MDAI $2.14
- Average True Range (ATR)
- ACRV 0.19
- MDAI 0.11
- MACD
- ACRV 0.02
- MDAI 0.01
- Stochastic Oscillator
- ACRV 16.06
- MDAI 43.60
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.